ClinicalTrials.gg
Not yet recruitingNCT07875413Updated Oct 15, 2026

Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy

A Phase 2 interventional study of Prizloncabtagene Autoleucel in Large B Cell Lymphoma, LBCL and Diffuse Large B Cell Lymphoma (DLBCL), sponsored by AbelZeta Inc.. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by AbelZeta Inc. · Phase 2, Interventional, and Treatment

Updated Oct 15, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States — 126 open to participants now, 217 under way, 18 of them phase 3. Lymphoma, Large B-Cell, Diffuse · United States.

Planned enrollment
329th of 963
55 · median 37
Started
2027
with 2 others
Phase 2
380 of 1,131
47 open now
Primary completion
2029-06
later than 180 of 216 live
Registered
1,129th of 1,131
by date

Among the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, this one is the 329th largest by planned enrollment of the 963 interventional ones that give a count, is one of 3 that started in 2027, is one of 380 in phase 2, reaches primary completion later than 180 of the 216 other live ones, and was the 1,129th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

126 of the 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States are open now. Recruiting first, the newest first:

121 more — sign in →

All 126 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,131 studies in Lymphoma, Large B-Cell, Diffuse with a site in United States, or all of them as a file.
02

Study summary

This Phase 2, multicenter, open-label study will evaluate the safety and efficacy of a single infusion of Prizloncel, an anti-CD19/CD20 chimeric antigen receptor T cells following lymphodepleting chemotherapy in participants with relapsed/refractory (r/r) diffuse large B-cell lymphoma post FDA approved, commercially available CAR T-cell therapy

Approximately 50 participants will undergo leukapheresis, lymphodepletion with fludarabine and cyclophosphamide, and infusion of Prizlon-cel. Participants will be followed for 24 months (approximately 2 years) to evaluate efficacy, safety, CAR T-cell persistence, pharmacokinetics/pharmacodynamics, and biomarkers. Long-term safety follow-up for gene therapy-related events will continue for up to 15 years following CAR T-cell infusion.

03

Conditions studied

  • Large B Cell Lymphoma
  • LBCL
  • Diffuse Large B Cell Lymphoma (DLBCL)
  • Relapse Diffuse Large B Cell Lymphoma
  • High Grade B Cell Lymphoma
  • FL
  • HGBL
  • Transformed Follicular Lymphoma (TFL)
  • Primary Mediastinal B Cell Lymphoma
  • PMBCL
  • HGBL With MYC and BCL2 and/or BCL6 Rearrangements

Keywords

  • LBCL
  • Large B Cell Lymphoma
  • Diffuse Large B Cell Lymphoma
  • CAR-T cell
  • CAR T-cell therapy
  • CAR T
  • CD19
  • CD20
  • Lymphoma
  • PBMCL
  • cell therapy
  • chimeric antigen receptor T-cell therapy
  • chimeric antigen receptor
  • Car-T
  • Follicular Lymphoma
  • TFL
  • MYC
  • BCL2
  • HGBL
  • High Grade B Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  1. Able to sign and date the Form (ICF)
  2. ≥18 years of age, at the time of signing informed consent
  3. Diagnosis of B-cell non-Hodgkin lymphoma (B-NHL), including the following neoplasms as defined by the 2022 WHO classification of lymphoid neoplasms:

    1. Diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS)
    2. Primary mediastinal large B-cell lymphoma (PMBCL)
    3. Transformed follicular lymphoma (tFL) (Pathology report is required to clarify DLBCL rather than follicular lymphoma (FL) with local/minor progression to DLBCL)
    4. Diffuse large B-cell lymphoma/high-grade B-cell lymphoma with MYC and BCL2 rearrangements (DLBCL/HGBL-MYC/BCL2)
    5. High-grade B-cell lymphoma (HGBL), NOS
    6. Follicular large B-cell lymphoma (FLBL) (At least 2 pathological diagnoses of follicular lymphoma grade 3B [FL3b] at different times are required, and the most recent pathology used for screening is FL3b or FLBL)
  4. R/R disease after ≥2 lines of standard therapy, including FDA approved, commercially available CAR T-cell therapy for at least 3 months since previous CAR T-cell therapy treatment.
  5. per the Lugano 2014 Classification

Key Exclusion Criteria:

  1. Prior hematopoietic stem cell transplantation (HSCT)
  2. ASCT within 12 weeks of leukapheresis
  3. Prior treatment with any CAR T-cell therapy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    Prizlon-cel

    Participants will receive: • Leukapheresis • Fludarabine • Cyclophosphamide • Single intravenous infusion of Prizlon-cel.

    Biological: Prizloncabtagene Autoleucel

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR, including CR rate and PR rate according to the Lugano Criteria 2014

    Time frame: Through Month 24

  2. Incidence and severity of adverse events (AEs)

    Evaluate the incidence, severity, and relationship of adverse events following C-CAR168 infusion, graded according to NCI CTCAE Version 6.0.

    Time frame: Through Month 24

Secondary outcomes

  1. Duration of Response (DOR)

    Duration of response from first objective response

    Time frame: Through Month 24

  2. Complete Response Rate

    Percentage of participants that received Prizlon-cel that achieve a complete response

    Time frame: Through Month 24

  3. Best Overall Response (BOR)

    Best overall response of participants that received Prizlon-cel

    Time frame: Through Month 24

  4. Time to Response

    Time of first objective response from Prizlon-cel infusion

    Time frame: Through Month 24

  5. Progression Free Survival (PFS)

    Time from enrollment until progression, relapse or death

    Time frame: Through Month 24

  6. Overall Survival (OS)

    Time from date of enrollment to the date of death from any cause.

    Time frame: Through Month 24

  7. Quantitative polymerase chain reaction (qPCR) to determine maximum plasma concentration of Prizloncel post infusion

    Characterize CAR T-cell expansion and persistence using qPCR to measure maximum plasma concentration (Cmax) after Prizloncel infusion

    Time frame: Through Month 24

  8. Area under the Curve (AUC) utilizing flow cytometry to determine Prizloncel persistence

    Characterize T-cell expansion and persistence utilizing flow cytometry to determine the AUC of Prizloncel in peripheral blood

    Time frame: Through Month 24

  9. Changes in CD19/CD20-positive cells in peripheral blood after Prizlon-cel infusion

    Changes in CD19/CD20-positive cells in peripheral blood after Prizlon-cel infusion utilizing flow cytometry

    Time frame: Through Month 24

07

Study locations

2 sites
  • Research Site
    Gilbert, Arizona 85234, United States
  • Research Site
    La Jolla, California 92037, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2027; primary completion for Jun 2029, 25 months later.

Of 54 industry-sponsored phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's planned 25 months is below that.

Counting every sponsor, half of 264 studies reached it within 53 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2026
First posted
Oct 15, 2026
StartEst.
May 2027
Primary completionEst.
Jun 2029
CompletionEst.
Dec 2030
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07875413
Lead sponsor
AbelZeta Inc.
Responsible party
Sponsor
First posted
Oct 15, 2026
Start date
May 2027 (estimated)
Primary completion
Jun 2029 (estimated)
Completion
Dec 2030 (estimated)
Last update
Oct 15, 2026

Study contacts

Kirstin Liechty, Head of Clinical Operations
Contact
kirstin.liechty@abelzeta.com
267-566-6081
Yihong Yao, PhD
study director · AbelZeta Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prizloncabtagene autoleucel

Start the discussion